KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Long-Term Investments: 2009-2025

Historic Long-Term Investments for Regeneron Pharmaceuticals (REGN) over the last 16 years, with Sep 2025 value amounting to $10.3 billion.

  • Regeneron Pharmaceuticals' Long-Term Investments rose 21.14% to $10.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $10.3 billion, marking a year-over-year increase of 21.14%. This contributed to the annual value of $8.9 billion for FY2024, which is 64.92% up from last year.
  • Regeneron Pharmaceuticals' Long-Term Investments amounted to $10.3 billion in Q3 2025, which was up 2.26% from $10.1 billion recorded in Q2 2025.
  • Regeneron Pharmaceuticals' Long-Term Investments' 5-year high stood at $10.3 billion during Q3 2025, with a 5-year trough of $3.5 billion in Q1 2021.
  • For the 3-year period, Regeneron Pharmaceuticals' Long-Term Investments averaged around $7.8 billion, with its median value being $7.7 billion (2024).
  • Per our database at Business Quant, Regeneron Pharmaceuticals' Long-Term Investments skyrocketed by 118.08% in 2021 and then dropped by 18.13% in 2023.
  • Regeneron Pharmaceuticals' Long-Term Investments (Quarterly) stood at $6.8 billion in 2021, then dropped by 3.60% to $6.6 billion in 2022, then fell by 18.13% to $5.4 billion in 2023, then surged by 64.92% to $8.9 billion in 2024, then rose by 21.14% to $10.3 billion in 2025.
  • Its Long-Term Investments was $10.3 billion in Q3 2025, compared to $10.1 billion in Q2 2025 and $9.3 billion in Q1 2025.